Status:
TERMINATED
Pilot Study Characterizing Adipose Tissue Leukocytes by Flow Cytometry/Microscopy in Lean, Obese and Psoriatic Subjects
Lead Sponsor:
Rockefeller University
Conditions:
Psoriasis
Obesity
Eligibility:
All Genders
18-65 years
Brief Summary
Obesity is an insulin resistance-associated metabolic disorder which is a hallmark of and risk factor for type 2 diabetes and the metabolic syndrome, often linked to cardiovascular disease, certain ca...
Detailed Description
Obesity is an insulin resistance-associated metabolic disorder which is a hallmark of and risk factor for type 2 diabetes and the metabolic syndrome. It is also often linked to cardiovascular disease,...
Eligibility Criteria
Inclusion
- Psoriatic lean cohort (BMI between 18-24.9 Kg/m2): moderate to severe plaque-type, at least 5% of BSA
- Psoriatic obese cohort (BMI between 30-40 Kg/m2): moderate to severe plaque-type, at least 5% of BSA
- Lean/non-psoriatic cohort: BMI between 18-24.9 Kg/m2
- Overweight/obese non-psoriatic cohort: BMI between 30-40 Kg/m2
- Subjects must be 18-65 years of age
Exclusion
- Having received any systemic treatment for psoriasis within the last 30 days
- history of bleeding disorder
- weight loss of 10 pounds in the last four weeks
- current smoker
- Known diagnosis of any unrelated autoimmune disease or inflammatory disease ( i.e. lupus, atopic dermatitis, rheumatoid arthritis).
- Currently taking NSAIDS, aspirin, (if \> once a week, stopped \<30 days ago). Aspirin 81mg may be permitted if the Framingham Risk Score is \< 10
- Having received any anti-inflammatory medication within the last 30 days
- Current use of any anti-coagulants
- LFTs \> 2 x upper normal limits
- HIV infection
- Pregnant
- Less than 6 weeks post partum
- history of cardiovascular disease (MI, CHF, CVA)
- Any cancer diagnosis within the last 5 years
- Symptoms of acute illness such as upper respiratory infection, bronchitis, gastroenteritis, or fever within 3 days of Visit 1
- Any medical, psychological or social condition that, in the opinion of the Investigator, would jeopardize the health or well-being of the participant during any study procedures or the integrity of the data
- ingestion of DHA or fish oil within last 90 days
- hypertension as defined as \> 140 systolic and \> 90 diastolic after 10 minutes of resting on 2 antihypertensives
- Use of statins within the last 30 days
Key Trial Info
Start Date :
February 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT01856647
Start Date
February 1 2013
End Date
December 1 2015
Last Update
December 21 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Rockefeller University
New York, New York, United States, 10065